COMMUNIQUÉS West-GlobeNewswire

Voting Rights and Shares Capital of the Company

11/10/2024 - 22:15

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE [...]

Conavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business Combination

11/10/2024 - 22:30

TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (formerly, “ Titan Medical Inc. ”) (“the “ Resulting Issuer ” or the “ Corporation ”) (TSX: TMD; OTC: TMDIF) is pleased to announce the completion of the [...]

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/10/2024 - 22:30

CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]

Bionano Announces Preliminary 3Q 2024 Revenues and Cash

10/10/2024 - 14:00

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third [...]

Construction of JinMed's New Facility Begins in Chuzhou, China

10/10/2024 - 14:00

Chuzhou City, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- JIN MEDICAL INTERNATIONAL LTD. (the "Company" or “JinMed”) (NASDAQ: ZJYL), an industrial leader in Assistive Technologies (“AT”), and a manufacturer and developer [...]

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

10/10/2024 - 14:00

Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for [...]

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

10/10/2024 - 14:00

Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that [...]

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

10/10/2024 - 14:05

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

10/10/2024 - 14:07

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a [...]

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

10/10/2024 - 14:30

SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced [...]

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

10/10/2024 - 14:30

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose ( [...]

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

10/10/2024 - 14:30

Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member Council ATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing [...]

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

10/10/2024 - 14:30

DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic [...]

Alpha Tau Treats First Patient with Recurrent Lung Cancer

10/10/2024 - 14:30

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today [...]

International Myeloma Foundation Launches Clinical Trial Matching Engine in Partnership with SparkCures

10/10/2024 - 14:45

SparkCures’ best-in-class clinical trial matching and navigation service is now accessible via myeloma.org. STUDIO CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is excited to [...]

NEXGEL Preannounces Expected Record Third Quarter 2024 Revenue of $2.85 Million, an Increase of Approximately 133% Year-Over-Year and 98% Sequentially

10/10/2024 - 15:00

LANGHORNE, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]

Labviva Named BostInno Fire Awards Honoree

10/10/2024 - 15:00

Company acknowledged for “pushing AI to the limits” BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Labviva , the leading AI procurement platform for life sciences, was named as an honoree of the 2024 BostInno Fire Awards in [...]

Amydis to Present First Ocular Tracer Designed to Detect Transthyretin Amyloidosis (ATTR) at AAOOP Conference

10/10/2024 - 15:00

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease-related molecular biomarkers in the eye, announced [...]

Spinach® Is the Number One Cannabis Brand in Canada

10/10/2024 - 15:00

TORONTO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, is proud to announce that its award-winning brand Spinach® has risen to the [...]